## Teva Innovative Medicine Pipeline

Preclinical

TEV-'279 Neuroscience

TEV-'288 Neuroscience

TEV-'287<sup>1</sup> Neuroscience

TEV-'6000 Neuroscience Phase 1

TEV-'408 Immunology

TEV-'192 Immunology & Neuroscience

> TEV-'278 Oncology

Phase 2

Duvakitug (TEV-'574)<sup>2</sup> Ulcerative Colitis & Crohn's Disease

Emrusolmin (TEV-'286)<sup>1</sup> Multiple System Atrophy Phase 3

Olanzapine LAI (TEV-'749) Schizophrenia

> ICS/SABA<sup>3</sup> (TEV-'248) Asthma

Technology platforms

Novel Biologic

Small Molecule Pipeline is current as of July 31, 2024

- 1. In collaboration with MODAG.
- 2. In collaboration with Sanofi
- 3. In collaboration with Launch Therapeutics

Teva innovative medicine pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.



## Teva Biosimilar Franchise

**Preclinical** 

Phase 3

**Approved** 

Commercial Biosimilar Products

TEV-'285

TEV-'191

TEV-'261

TEV-'289

TEV-'284 / TEV-'2941

TEV-'2921

TEV-'2951

TEV-'296<sup>1</sup>

TEV-'316<sup>2</sup>

Biosimilar to Prolia® (denosumab)

Biosimilar to Xgeva® (denosumab)

Biosimilar to Xolair® (omalizumab)

Biosimilar to Eylea® (aflibercept)¹

Biosimilar to Simponi<sup>®</sup> (golimumab)<sup>1</sup>

Biosimilar to Simponi Aria<sup>®</sup> (golimumab)<sup>1</sup>





## Pipeline is current as of July 31, 2024

- 1. In collaboration with Alvotech for the U.S. Market
- 2. In collaboration with mAbxience
- 3. In collaboration with Celltrion in the U.S. and Canada
- 4. In collaboration with BioEq in the UK (marketed as ONGAVIA®), in the EU (marketed as RANIVISIO®) and in Canada (marketed as RANOPTO™)

